Pilot production payment for LabTech
Friday, 12 September, 2008
LabTech Systems (ASX: LBT) has sent pilot production units of its MicroStreak technology to partner bioMérieux, triggering a $1.74 million milestone payment.
LabTech Systems signed an exclusive license agreement with bioMérieux last year. The French diagnostics giant will market the technology under its PREVI Isola brand.
The technology is a high-speed robotic platform for agar plate streaking in microbiology and pathology labs.
This payment brings the total revenue from the agreement to $6.67 million.
The PREVI Isola will be on sale later this year. LabTech Systems also expects royalty payments to begin from January 1 next year.
Multiple myeloma treatment reprograms patients' own immune cells
An Australian and Victorian Government funding agreement has allowed eligible Australians with...
Could 'fusion proteins' reduce errors in a promising gene-editing tool?
Gene-editing tool CRISPR-Cas9 is used, among many things, to engineer new cancer immunotherapies....
Cancer research and clinical trials at the core of new centre
The Australian Cancer Research Foundation Centre for Dynamic Immuno-Oncology (CDIO) has been...
